Cline Scientific has
entered into a collaboration with AstraZeneca to utilise Cline’s gradient
technology as part of the multi-country European MSCA-ITN network, V.A Cure. V.A Cure is a Horizon
2020 funded project which aims to uncover core mechanisms of vascular anomalies
and to leverage this information for establishing new therapeutics for vascular
disease. The project consists of 14 individual research projects across seven
academic labs and two industry partners.
Vascular anomalies are defects of the vascular system that can be either with blood or
lymph vessels. Many vascular anomalies are congenial and inherited, but they can
also be brought on by events such as trauma and pregnancy. Vascular anomalies
can be malformations or tumours, which range from harmless to life-threatening.
As part of one of the V.A
Cure projects, a Ph.D. student at AstraZeneca will use Cline’s gradient surface
technology and methods in the development of protocols with the aim of
differentiating iPS cells into cell types which are relevant for vascular anomalies.
The project also aims to transform these stem cells to form vascular tissue and
create a homogenous cell line for vascular anomalies which has not previously
been possible. Should the project prove
successful, the protocols and cell lines have the potential to be used in other
studies and for the generation of novel treatments.
“This project represents an
exciting possibility for Cline’s surface technology to be applied to a
different type of cell and disease area. The use of Cline’s gradient surfaces in
the V.A Cure project serves to further validate the use of nanogradient
surfaces in cellular research and therapy development.”says Patrik Sundh, CEO, Cline
Cline gradient surfaces and
stem cell differentiation method have already been successful to drive the
differentiation of iPS cells into human cartilage. This achievement lead to the
development of Cline’s regenerative medicine therapy project, StemCART.
Cline Scientific is a
member of AstraZeneca’s BioVentureHub in Gothenburg, Sweden.
develops advanced cancer diagnostics and regenerative medicine treatments. The
company is working heavily with R&D through joint collaborations with
pharmaceutical companies and academic researchers around the world. The focus
is on projects in the cancer diagnostic and stem cell therapy fields since
Clines nanotechnology here provides unmet solutions to critical challenges and
functions. The unique patented surface nanotechnology is used in cell-based
products and processes to drive projects within Life Science into and through
the clinical phase.